Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dat Ngo

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Leukemia & Lymphoma|April 18, 2024
High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapyJose Tinajero, Dat Ngo, Jianying Zhang, et al.
American Journal of Hematology|March 15, 2021
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)Amandeep Salhotra, Ahmed Aribi, Dat Ngo, et al.
American Journal of Hematology|July 7, 2020
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemiaIbrahim Aldoss, Jianying Zhang, Matthew Mei, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 22, 2025
Quantum Phase Transitions in Graphene Coupled to a Twisted WSe<sub>2</sub> Moiré FerroelectricityBudhi Singh, Yasir Hassan, Nasir Ali, et al.
British Journal of Haematology|September 1, 2025
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemiaHoda Pourhassan, Jose Tinajero, Huiyan Ma, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)Brian J Ball, Shukaib Arslan, Paul Koller, et al.
Bone Marrow Transplantation|June 10, 2021
Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantationStephanie Mac, Dat Ngo, Dongyun Yang, et al.
Cancer|October 11, 2021
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemiaIbrahim Aldoss, Salman Otoukesh, Jianying Zhang, et al.
Cancer Medicine|April 21, 2023
Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experienceIdoroenyi Amanam, Janny Yao, Alfredo Puing, et al.
American Journal of Hematology|May 28, 2024
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemiaTamer Othman, Paul Koller, Ni-Chun Tsai, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Leukemia & Lymphoma|April 18, 2024
High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapyJose Tinajero, Dat Ngo, Jianying Zhang, et al.
American Journal of Hematology|March 15, 2021
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)Amandeep Salhotra, Ahmed Aribi, Dat Ngo, et al.
American Journal of Hematology|July 7, 2020
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemiaIbrahim Aldoss, Jianying Zhang, Matthew Mei, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 22, 2025
Quantum Phase Transitions in Graphene Coupled to a Twisted WSe<sub>2</sub> Moiré FerroelectricityBudhi Singh, Yasir Hassan, Nasir Ali, et al.
British Journal of Haematology|September 1, 2025
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemiaHoda Pourhassan, Jose Tinajero, Huiyan Ma, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)Brian J Ball, Shukaib Arslan, Paul Koller, et al.
Bone Marrow Transplantation|June 10, 2021
Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantationStephanie Mac, Dat Ngo, Dongyun Yang, et al.
Cancer|October 11, 2021
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemiaIbrahim Aldoss, Salman Otoukesh, Jianying Zhang, et al.
Cancer Medicine|April 21, 2023
Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experienceIdoroenyi Amanam, Janny Yao, Alfredo Puing, et al.
American Journal of Hematology|May 28, 2024
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemiaTamer Othman, Paul Koller, Ni-Chun Tsai, et al.
Pageof 9